Clinical Trials Logo

Oncogenic Osteomalacia clinical trials

View clinical trials related to Oncogenic Osteomalacia.

Filter by:
  • None
  • Page 1

NCT ID: NCT03510455 Terminated - Clinical trials for Tumor-Induced Osteomalacia

BGJ398 for the Treatment of Tumor-Induced Osteomalacia

Start date: February 27, 2019
Phase: Phase 2
Study type: Interventional

Background: People with tumor-induced osteomalacia (TIO) have small tumors that may cause low blood phosphorus, weak muscles, bone pain, and broken bones. The tumors may be so small they are hard to find or impossible to remove. Researchers want to test a drug that may help treat TIO. Objective: To see how the drug BGJ398 affects people with tumor-induced osteomalacia. Eligibility: People ages 18-85 who are in NIH protocol 01-D-0184 and have TIO that cannot be found or easily removed Design: At every study visit, participants will have: - Medical history - Physical exam - Blood and urine tests - Questions about their health and fatigue At the screening visit, participants will also have a heart and eye tests. They may have other tests to find their tumor. The baseline visit will be a 1-week stay in the clinic. Participants will have the regular study tests, plus: - Their first dose of the study drug capsules - Blood and urine collected every 2-4 hours for 24 hours. A thin plastic tube will be inserted in a vein to collect blood. - Heart and kidney ultrasounds - Activities that test strength - 6-minute walk test Participants will take the study drug for six 1-month cycles. In each cycle, participants will: - Take the study drug every day for 4 weeks. - Have 1 visit. Participants will collect their urine for 24 hours and have their blood drawn. Participants will have the regular study tests and repeat some baseline tests. - Have blood and urine tests at their local lab. Participants will have 1 visit at the end of the last cycle and another 3 months later....

NCT ID: NCT01524016 Recruiting - Mesenchymal Tumor Clinical Trials

68Ga-DOTATATE PET/CT in Oncogenic Osteomalacia

Start date: December 2011
Phase: Early Phase 1
Study type: Interventional

Oncogenic osteomalacia is rare disease predominantly caused by a small, somatostatin receptor positive mesenchymal tumor, which is frequently hidden in an unusual anatomical site and often goes undetected by conventional imaging. A permanent cure of the disease relies on exactly localizing the tumor and completely removing it. 68Ga-DOTATATE PET/CT is a novel scan that might have improved sensitivity and resolution specifically for somatostatin receptor positive tumors. The investigators will scan the suspicious and confirmed patients of oncogenic osteomalacia and compare it to 99mTc-HYNIC-TOC SPECT/CT and 18F-FDG PET/CT to see if it improves patient care.